Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study.

ABSTRACT:

Purpose

Antivascular endothelial growth factor (anti-VEGF) therapy is a promising treatment approach for patients with recurrent glioblastoma. This single-arm phase II study evaluated the efficacy of aflibercept (VEGF Trap), a recombinantly produced fusion protein that scavenges both VEGF and placental growth factor in patients with recurrent malignant glioma.

Patients and methods

Forty-two patients with glioblastoma and 16 patients with anaplastic glioma who had received concurrent radiation and temozolomide and adjuvant temozolomide were enrolled at first relapse. Aflibercept 4 mg/kg was administered intravenously on day 1 of every 2-week cycle.

Results

The 6-month progression-free survival rate was 7.7% for the glioblastoma cohort and 25% for patients with anaplast

SUBMITTER: de Groot JF 

PROVIDER: S-EPMC3139373 | biostudies-literature | 2011 Jul

REPOSITORIES: biostudies-literature